

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY. THIS IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA. Initial public offer of equity shares on the main board of BSE Limited (“**BSE**”) and National Stock Exchange of India Limited (“**NSE**”, and together with BSE, the “**Stock Exchanges**”) in compliance with Chapter II of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (“**SEBI ICDR Regulations**”).



(Please scan this QR code to view the Corrigendum)



ANTHEM BIOSCIENCES LIMITED

Our Company was originally incorporated as “*Anthem Biosciences Private Limited*” under the provisions of the Companies Act, 1956, pursuant to a certificate of incorporation dated June 13, 2006, issued by the Registrar of Companies, Karnataka at Bengaluru (“**RoC**”). Subsequently, our Company was converted from a private company to a public company, pursuant to a board resolution dated October 18, 2024 and a resolution passed in the extraordinary general meeting of our Shareholders held on October 18, 2024 following which the name of our Company was changed to “*Anthem Biosciences Limited*” and a certificate of incorporation consequent upon conversion to public limited company was issued by the RoC on December 10, 2024. For further details in relation to the changes in the name and registered office of our Company, see “*History and Certain Corporate Matters – Changes in our Registered Office*” on page 234 of the red herring prospectus dated July 8, 2025 (“**RHP**” or “**Red Herring Prospectus**”) filed with the RoC.

Registered and Corporate Office: No. 49, F1 & F2, Canara Bank Road, Bommasandra Industrial Area, Phase 1, Bommasandra, Bangalore, Karnataka, India, 560 099;
Telephone: +91 080 6672 4000; **Contact Person:** Divya Prasad, Company Secretary and Compliance Officer;
E-mail: investors.abl@anthembio.com; **Website:** www.anthembio.com; **Corporate Identity Number:** U24233KA2006PLC039703.

OUR PROMOTERS: AJAY BHARDWAJ, GANESH SAMBASIVAM, K RAVINDRA CHANDRAPPA AND ISHAAN BHARDWAJ

NOTICE TO INVESTORS
CORRIGENDUM TO THE RED HERRING PROSPECTUS DATED July 8, 2025 (THE “CORRIGENDUM”)

INITIAL PUBLIC OFFERING OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹2 EACH (“EQUITY SHARES”) OF ANTHEM BIOSCIENCES LIMITED (“COMPANY” OR “ISSUER”) FOR CASH AT A PRICE OF ₹[●] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹[●] PER EQUITY SHARE) (“OFFER PRICE”) AGGREGATING UP TO ₹33,950.00 MILLION (THE “OFFER”) THROUGH AN OFFER FOR SALE AGGREGATING UP TO ₹ 33,950.00 MILLION COMPRISING UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹ 2 EACH BY GANESH SAMBASIVAM AGGREGATING UP TO ₹3,500.00 MILLION, UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹2 EACH BY K RAVINDRA CHANDRAPPA, AGGREGATING UP TO ₹3,500.00 MILLION AND UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹2 EACH BY VIRIDITY TONE LLP, AGGREGATING UP TO ₹13,250.00 MILLION AND UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹2 EACH BY PORTSMOUTH TECHNOLOGIES LLC, AGGREGATING UP TO ₹3,200.00 MILLION AND UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹2 EACH BY MALAY J BARUA, AGGREGATING UP TO ₹3,200.00 MILLION AND UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹2 EACH BY RUPESH N KINEKAR, AGGREGATING UP TO ₹3,200.00 MILLION AND UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹2 EACH BY SATISH SHARMA, AGGREGATING UP TO ₹3,200.00 MILLION AND UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹2 EACH BY PRAKASH KARIABETTAN, AGGREGATING UP TO ₹800.00 MILLION AND UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹2 EACH BY K RAMAKRISHNAN, AGGREGATING UP TO ₹100.00 MILLION (COLLECTIVELY, “SELLING SHAREHOLDERS” AND SUCH OFFER FOR SALE OF EQUITY SHARES BY THE SELLING SHAREHOLDERS, THE “OFFER FOR SALE”). THE OFFER SHALL CONSTITUTE [●] % OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE OFFER INCLUDES A RESERVATION OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹ 2 EACH, AGGREGATING UP TO ₹82.50 MILLION (CONSTITUTING UP TO [●]% OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL) FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (“EMPLOYEE RESERVATION PORTION”). OUR COMPANY, IN CONSULTATION WITH THE BRLMS MAY OFFER A DISCOUNT OF UP TO [●] OF THE OFFER PRICE TO ELIGIBLE EMPLOYEES BIDDING IN THE EMPLOYEE RESERVATION PORTION (“EMPLOYEE DISCOUNT”), SUBJECT TO NECESSARY APPROVALS AS MAY BE REQUIRED. THE OFFER LESS THE EMPLOYEE RESERVATION PORTION IS HEREINAFTER REFERRED TO AS THE “NET OFFER”. THE OFFER AND THE NET OFFER SHALL CONSTITUTE [●]% AND [●]% OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY, RESPECTIVELY.

This Corrigendum is in reference to the Red Herring Prospectus filed with the Registrar of Companies, Karnataka at Bengaluru (“**RoC**”) and thereafter with the Securities and Exchange Board of India (“**SEBI**”), BSE Limited (“**BSE**”) and the National Stock Exchange of India Limited (“**NSE**”, together with BSE, the “**Stock Exchanges**”) on July 8, 2025. In this regard, potential Bidders should note that the percentage available for (i) allocation for QIBs on a proportionate basis is not more than 50% of the “Net Offer”, (ii) Non Institutional Investors is not less than 15% of the “Net Offer”, and (iii) Retail Institutional Investors is not less than 35% of the “Net Offer”, in each case instead of “the Offer”, on the inside cover page, and pages 7, 8, 80, 395, 396, 398, 400 and 416 of the RHP. Accordingly, all references to allocation in the RHP, to the extent they relate to the context of the foregoing, should be read as “the Net Offer” instead of “the Offer”.

The information above modifies and updates the information (as applicable) in the RHP. The RHP accordingly stands amended to the extent stated hereinabove and the above changes are to be read in conjunction with the RHP. Please note that this Corrigendum does not reflect any other changes that have occurred between the date of filing of the RHP and the date of the Corrigendum, and the relevant changes shall be reflected in the Prospectus as and when filed with the RoC, SEBI and the Stock Exchanges.

This Corrigendum shall be available on the website of SEBI at www.sebi.gov.in, the website of Stock Exchanges at www.nseindia.com and www.bseindia.com, the website of our Company at www.anthembio.com and the websites of the Book Running Lead Managers, namely, JM Financial Limited at www.jmfi.com, Citigroup Global Markets India Private Limited at https://www.citigroup.com/global/about-us/global-presence/india/disclaimer, J.P. Morgan India Private Limited at www.jpmpil.com and Nomura Financial Advisory and Securities (India) Private Limited at https://www.nomuraholdings.com/company/group/asia/nfaspl.html. All capitalized terms used in this Corrigendum shall, unless the context otherwise requires, have the meanings ascribed to them in the RHP.

BOOK RUNNING LEAD MANAGERS			
		J.P.Morgan	NOMURA
JM Financial Limited 7 th Floor, Cnergy, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, Maharashtra, India Telephone: +91 22 6630 3030 E-mail: Anthem.ipo@jmfi.com Investor grievance E-mail: grievance.ibd@jmfi.com Website: www.jmfi.com Contact person: Prachee Dhuri SEBI registration number: INM000010361	Citigroup Global Markets India Private Limited 1202, 12 th Floor, First International Financial Centre G-Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 098, Maharashtra, India Telephone: +91 22 6175 9999 E-mail: anthem.ipo@citi.com Investor grievance E-mail: investors.cgmb@citi.com Website: https://www.citigroup.com/global/about-us/global-presence/india/disclaimer Contact person: Abhishek Mawandiya SEBI registration number: INM000010718	J.P. Morgan India Private Limited J.P. Morgan Tower, Off CST Road, Kalina, Santacruz East, Mumbai - 400 098, Maharashtra, India Telephone: +91 22 6157 3000 E-mail: anthem_ipo@jpmorgan.com Investor grievance e-mail: investorsmb.jpmpil@jpmorgan.com Website: www.jpmpil.com Contact person: Tarang Shah/ Rishank Chheda SEBI registration no.: INM000002970	Nomura Financial Advisory and Securities (India) Private Limited Ceejay House, Level 11, Plot F, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai - 400 018, Maharashtra, India Telephone: +91 22 4037 4037 E-mail: anthembioipo@nomura.com Investor Grievance E-mail: investorgrievances-in@nomura.com Website: www.nomuraholdings.com/company/group/asia/india/index.html Contact person: Vishal Kanjanil/ Chirag Shah SEBI Registration No.: INM000011419
REGISTRAR TO THE OFFER		COMPANY SECRETARY AND COMPLIANCE OFFICER	
 KFin Technologies Limited Selenium, Tower B, Plot No- 31 and 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddy - 500 032, Telangana, India Telephone: +91 40 6716 2222, E-mail: anthem.ipo@kfintech.com Investor grievance E-mail: einward.ris@kfintech.com, Website: www.kfintech.com Contact person: M. Murali Krishna, SEBI registration number: INR000000221		Divya Prasad No. 49, F1 & F2, Canara Bank Road, Bommasandra Industrial Area, Phase 1, Bommasandra, Bangalore, Karnataka, India, 560 099; Telephone: +91 080 6672 4051, E-mail: compliance.abl@anthembio.com Investors may contact the Company Secretary and Compliance Officer or the Registrar to the Offer in case of any pre-Offer or post-Offer related grievances including non-receipt of letters of Allotment, non-credit of Allotted Equity Shares in the respective beneficiary account, non-receipt of refund orders or non-receipt of funds by electronic mode, etc. For all Issue related queries and for redressal of complaints, Investors may also write to the BRLMs.	

Place: Bengaluru
Date: July 11, 2025

For **ANTHEM BIOSCIENCES LIMITED**
On behalf of the Board of Directors
Sd/-
Divya Prasad
Company Secretary and Compliance Officer

ANTHEM BIOSCIENCES LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the RHP with RoC and the Stock Exchanges on July 8, 2025. The RHP is available on the website of SEBI at www.sebi.gov.in, as well as on the websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, on the website of the Company at www.anthembio.com; and on the websites of the BRLMs, i.e. JM Financial Limited, Citigroup Global Markets India Private Limited, J.P. Morgan India Private Limited and Nomura Financial Advisory and Securities (India) Private Limited at www.jmfi.com, https://www.citigroup.com/global/about-us/global-presence/india/disclaimer, www.jpmpil.com and www.nomuraholdings.com/company/group/asia/india/index.html, respectively. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see ‘*Risk Factors*’ on page 34 of the RHP filed with SEBI and the Stock Exchanges, when filed. Potential Bidders should not rely on the DRHP filed with SEBI and the Stock Exchanges for making any investment decision and should instead rely on the RHP, for making investment decision. This announcement is not an offer of securities for sale in the United States or elsewhere. This announcement has been prepared for publication in India only and is not for publication or distribution, directly or indirectly, in or into the United States. The Equity Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”) and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are only being offered and sold (a) within the United States solely to persons who are reasonably believed to be “qualified institutional buyers” (as defined in Rule 144A under the U.S. Securities Act) in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act, and (b) outside the United States in “offshore transactions” as defined in and in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales occur. There will be no public offering in the United States.